ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2464

B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature
Abstract Number: 1511

B-Cell Recovery in a Randomized Controlled Trial of B-Cell Depletion with Obinutuzumab for the Treatment of Proliferative Lupus Nephritis
Abstract Number: 2010

B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort
Abstract Number: 1042

B-line of Lung Ultrasound Reflects Different Morphological Features on Chest HRCT Between Interstitial Lung Disease Associated with Systemic Sclerosis and Myositis
Abstract Number: 0450

Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting
Abstract Number: 0998

Barriers and Facilitators for Osteoporosis and Sarcopenia Care for Persons Living with HIV in Peru: HIV Physician and Coordinator Perspectives
Abstract Number: 0183

Barriers and Facilitators to Recruiting Underrepresented Participants for Clinical Trials: Insights from the Lupus Clinical Investigators Network (LuCIN)
Abstract Number: 0172

Barriers and Strategies to Enhance Patient Research Partner Involvement in Rheumatology Research: A Systematic Literature Review
Abstract Number: 1028

Barriers to Total Joint Arthroplasty for Patients Residing in High-Poverty Communities
Abstract Number: 0358

Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis Associated Lung Disease (SJIA-LD) Cohort
Abstract Number: 1074

Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Abstract Number: 1284

Baseline Data’s Role in Predicting All-cause Mortality in Chinese Rheumatoid Arthritis Patients: Findings from the China Registry of Rheumatoid Arthritis (CREDIT) Study
Abstract Number: 2539

Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA
Abstract Number: 0594

Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease
Abstract Number: 0440

Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 1565

Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months
Abstract Number: 1562

Behcet’s Disease Coagulopathy in a Racially Diverse Patient Population
Abstract Number: 0692

Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity
Abstract Number: 2021

Beliefs, Attitudes, and Preferences of Patients with Rheumatoid Arthritis (RA) and Concomitant Cancer with Respect to RA Therapy
Abstract Number: 1651

Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Abstract Number: 0678

Benralizumab in Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1439

Better Drug Retention on anti-IL17A Compared to Anti-TNF Therapy Despite Its Inferior Effect on Composite Joint Indexes and Quality of Life in Patients with PsA–analysis from the Czech Biologics Registry ATTRA
Abstract Number: 1198

Bicycling Is Not Associated with New Knee Pain or Disease Progression over 48 Months in Those with Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 0525

Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Abstract Number: 1433

Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
Abstract Number: 2250

Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
Abstract Number: 0526

Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Abstract Number: 1437

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study
Abstract Number: 2252

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study
Abstract Number: 0523

Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Abstract Number: 1441

Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial
Abstract Number: 0527

Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
Abstract Number: 1415

Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD‑Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies
Abstract Number: 0510

Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
Abstract Number: 2230

Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label Extension up to 1 Year
Abstract Number: 2255

Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
Abstract Number: 2249

Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
Abstract Number: 0421

Bioinformatics Platform to Study the Genetics of Biologic DMARD Non-responders: Design and Protocol of the RA Non-responders to Treatment (RANT) Study
Abstract Number: 0457

Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival
Abstract Number: 1066

Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples
Abstract Number: 2149

Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors
Abstract Number: 0391

Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis
Abstract Number: 0498

Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)
Abstract Number: 1302

Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study
Abstract Number: 1780

Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study
Abstract Number: 2443

Blockade of OX40/OX40L Signaling Using anti-OX40L Ameliorates Systemic Lupus Erythematosus
Abstract Number: 1693

Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures
Abstract Number: 1147

Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function
Abstract Number: 1829

Blood-derived Extracellular Vesicles as Potential Diagnostic Biomarker in Fibromyalgia Syndrome
Abstract Number: 1465

Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis
Abstract Number: 1930

Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series
Abstract Number: 0570

BLyS Levels Are Elevated in Systemic Lupus Erythematosus Patients with Neuropsychiatric Manifestations
Abstract Number: 2004

Bone Health Following Bariatric Surgery: A Single Center Quality Improvement Study
Abstract Number: 1300

Bone Marrow Edema in MRI Is More Associated with Rapid Radiographic Progression Than Clinically Relevant Radiographic Progression
Abstract Number: 1364

Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Abstract Number: PP04

Bouncing Back: How I Found My Running Shoes Using a Rebounder for My Psoriatic Arthritis
Abstract Number: 2258

Brain Activity Patterns and Behavioural Performance in SLE Patients During a Spatial Working Memory and Sustained Attention Task
Abstract Number: 1824

Breakthrough COVID-19 and Severity After Vaccination Among Pregnant Persons with Rheumatic Diseases
Abstract Number: 0225

Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study
Abstract Number: 0462

Breastfeeding Intention in Systemic Lupus Erythematosus Patients
Abstract Number: 1176

Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
Abstract Number: 0504

Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature
Abstract Number: 2261

Burden of Flare and Organ Damage in Systemic Lupus Erythematosus (SLE) in the Asia Pacific Region: A Multicenter Cohort Study
Abstract Number: 2001

Burden of Metabolic Bone Disease in Patients with IgG4-Related Disease with and Without Autoimmune Pancreatitis
Abstract Number: 0308

Burden of Osteoarthritis Attributable to High BMI in 38 OECD Countries: A Benchmarking Analysis

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].